Programs 2018-08-02T15:04:43-04:00


Ophidion’s CNS Carrier Technology (OCCT) Derived Programs

Ophidion is addressing the problem of drug delivery into the CNS with an innovative and patented blood-brain-barrier traversing technology with proven preclinical proof-of-concept in animal models of cognition and pain. Multiple programs could potentially enter into the clinic in the next 2-3 years, addressing significant unmet needs in rare diseases as well as large markets. These include diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease), Huntington’s disease (HD), and Analgesia (an opioid-sparing approach to treat nociceptive pain).


Cognition (OCCT – lynx1 siRNA)
Huntington’s (OCCT – HTT siRNA)
Analgesia (OCCT – NT)

Anxiety Program

In addition, Ophidion has an Anxiety Program with a patented companion biomarker diagnostic that is positioned to start pivotal trials.